{
  "data": [
    {
      "id": "1",
      "company": "Merck & Co Inc.",
      "ticker": "MRK",
      "drug": "KEYTRUDA",
      "treatment": "Treatment of patients with platinum-resistant recu...",
      "pdufaDate": "2026-02-20",
      "approvalType": "NDA",
      "priority": "Standard",
      "status": "Pending",
      "description": "FDA decision on KEYTRUDA plus chemotherapy with or without bevacizumab for treatment of patients with platinum-resistant recurrent ovarian cancer"
    },
    {
      "id": "2",
      "company": "VANDA PHARMACEUTICALS",
      "ticker": "VNDA",
      "drug": "Bysanti",
      "treatment": "The acute treatment of bipolar i disorder and the ...",
      "pdufaDate": "2026-02-21",
      "approvalType": "NDA",
      "priority": "Standard",
      "status": "Pending",
      "description": "FDA decision on Bysanti (milsaperidone) for the acute treatment of bipolar I disorder and the treatment of schizophrenia"
    },
    {
      "id": "3",
      "company": "Eton Pharmaceuticals, Inc",
      "ticker": "ETON",
      "drug": "ET-600",
      "treatment": "Central diabetes insipidius, also known as arginin...",
      "pdufaDate": "2026-02-25",
      "approvalType": "NDA",
      "priority": "Standard",
      "status": "Pending",
      "description": "FDA decision on ET-600 for the treatment of central diabetes insipidius, also known as arginine vasopressin deficiency"
    },
    {
      "id": "4",
      "company": "Otsuka Holdings Co., Ltd.",
      "ticker": "OTSKF",
      "drug": "INQOVI",
      "treatment": "Adults with newly diagnosed acute myeloid leukemia...",
      "pdufaDate": "2026-02-25",
      "approvalType": "NDA",
      "priority": "Standard",
      "status": "Pending",
      "description": "FDA decision on INQOVI plus venetoclax as a treatment for adults with newly diagnosed acute myeloid leukemia (AML) who are ineligible for intensive induction chemotherapy"
    },
    {
      "id": "5",
      "company": "Sanofi SA",
      "ticker": "SNY",
      "drug": "Dupixent",
      "treatment": "Various conditions",
      "pdufaDate": "2026-02-28",
      "approvalType": "NDA",
      "priority": "Standard",
      "status": "Pending",
      "description": "FDA decision on Dupixent in adults and children aged 6 years and older with allergic fungal rhinosinusitis (AFRS)."
    },
    {
      "id": "6",
      "company": "Regeneron Pharmaceuticals Inc",
      "ticker": "REGN",
      "drug": "Dupixent",
      "treatment": "Various conditions",
      "pdufaDate": "2026-02-28",
      "approvalType": "NDA",
      "priority": "Standard",
      "status": "Pending",
      "description": "FDA decision on Dupixent in adults and children aged 6 years and older with allergic fungal rhinosin"
    },
    {
      "id": "7",
      "company": "Ascendis Pharma A/S",
      "ticker": "ASND",
      "drug": "TransCon CNP",
      "treatment": "Children with achondroplasia",
      "pdufaDate": "2026-02-28",
      "approvalType": "NDA",
      "priority": "Standard",
      "status": "Pending",
      "description": "FDA decision on TransCon CNP (navepegritide) for the treatment of children with achondroplasia"
    },
    {
      "id": "8",
      "company": "Biomarin Pharmaceutical Inc.",
      "ticker": "BMRN",
      "drug": "PALYNZIQ",
      "treatment": "Various conditions",
      "pdufaDate": "2026-02-28",
      "approvalType": "NDA",
      "priority": "Standard",
      "status": "Pending",
      "description": "FDA decision on PALYNZIQ to expand treatment to include adolescents aged 12-17 with phenylketonuria"
    },
    {
      "id": "9",
      "company": "Lantheus Holdings Inc.",
      "ticker": "LNTH",
      "drug": "New formulation of F18",
      "treatment": "Various conditions",
      "pdufaDate": "2026-03-06",
      "approvalType": "NDA",
      "priority": "Standard",
      "status": "Pending",
      "description": "FDA decision on new formulation of F18 PSMA-targeted PET imaging agent to determine the presence or absence of recurrent and/or metastatic prostate cancer."
    },
    {
      "id": "30",
      "company": "Bristol Myers Squibb Co.",
      "ticker": "BMY",
      "drug": "Sotyktu",
      "treatment": "Adults with active psoriatic arthritis",
      "pdufaDate": "2026-03-06",
      "approvalType": "NDA",
      "priority": "Standard",
      "status": "Pending",
      "description": "FDA decision on Sotyktu for the treatment of adults with active psoriatic arthritis."
    },
    {
      "id": "31",
      "company": "Aldeyra Therapeutics, Inc.",
      "ticker": "ALDX",
      "drug": "Reproxalap",
      "treatment": "The treat of dry eye disease",
      "pdufaDate": "2026-03-16",
      "approvalType": "NDA",
      "priority": "Standard",
      "status": "Pending",
      "description": "FDA decision on Reproxalap for the treat of dry eye disease"
    },
    {
      "id": "32",
      "company": "Rhythm Pharmaceuticals, Inc.",
      "ticker": "RYTM",
      "drug": "IMCIVREE",
      "treatment": "Acquired hypothalamic obesity",
      "pdufaDate": "2026-03-20",
      "approvalType": "NDA",
      "priority": "Standard",
      "status": "Pending",
      "description": "FDA decision on expanded use of IMCIVREE for the treatment of acquired hypothalamic obesity"
    },
    {
      "id": "33",
      "company": "GSK plc",
      "ticker": "GSK",
      "drug": "Linerixibat",
      "treatment": "Cholestatic pruritus in patients with primary bili...",
      "pdufaDate": "2026-03-24",
      "approvalType": "NDA",
      "priority": "Standard",
      "status": "Pending",
      "description": "FDA decision on Linerixibat for the treatment of cholestatic pruritus in patients with Primary Biliary Cholangitis"
    },
    {
      "id": "34",
      "company": "Rocket Pharmaceuticals, Inc.",
      "ticker": "RCKT",
      "drug": "KRESLADI",
      "treatment": "For severe leukocyte adhesion deficiency-i",
      "pdufaDate": "2026-03-28",
      "approvalType": "NDA",
      "priority": "Standard",
      "status": "Pending",
      "description": "FDA decision on KRESLADI for the treatment of for severe Leukocyte Adhesion Deficiency-I"
    },
    {
      "id": "35",
      "company": "Lantheus Holdings Inc.",
      "ticker": "LNTH",
      "drug": "LNTH-2501, a PET Diagnostic Imaging Kit",
      "treatment": "Use with pet imaging for localization of somatosta...",
      "pdufaDate": "2026-03-29",
      "approvalType": "NDA",
      "priority": "Standard",
      "status": "Pending",
      "description": "FDA decision on LNTH-2501 for use with PET imaging for localization of somatostatin receptor-positive (SSTR+) neuroendocrine tumors in adult and pediatric patients."
    },
    {
      "id": "36",
      "company": "Biogen Inc.",
      "ticker": "BIIB",
      "drug": "Nusinersen",
      "treatment": "People living with spinal muscular atrophy (sma)",
      "pdufaDate": "2026-04-03",
      "approvalType": "NDA",
      "priority": "Standard",
      "status": "Pending",
      "description": "FDA decision on high-dose regimen of nusinersen for people living with spinal muscular atrophy (SMA)"
    },
    {
      "id": "20",
      "company": "Denali Therapeutics Inc.",
      "ticker": "DNLI",
      "drug": "Tividenofusp alfa",
      "treatment": "Hunter syndrome",
      "pdufaDate": "2026-04-05",
      "approvalType": "NDA",
      "priority": "Standard",
      "status": "Pending",
      "description": "FDA decision on Tividenofusp alfa for the treatment of Hunter syndrome"
    },
    {
      "id": "37",
      "company": "Royalty Pharma plc",
      "ticker": "RPRX",
      "drug": "Tividenofusp alfa",
      "treatment": "Hunter syndrome",
      "pdufaDate": "2026-04-05",
      "approvalType": "NDA",
      "priority": "Standard",
      "status": "Pending",
      "description": "FDA decision on Tividenofusp alfa for the treatment of Hunter syndrome"
    },
    {
      "id": "21",
      "company": "Astellas Pharma Inc.",
      "ticker": "ALPMY",
      "drug": "PADCEV",
      "treatment": "Patients with muscle-invasive bladder cancer who a...",
      "pdufaDate": "2026-04-07",
      "approvalType": "NDA",
      "priority": "Standard",
      "status": "Pending",
      "description": "FDA decision on PADCEV plus KEYTRUDA for patients with muscle-invasive bladder cancer who are ineligible for cisplatin-containing chemotherapy"
    },
    {
      "id": "22",
      "company": "Pfizer Inc.",
      "ticker": "PFE",
      "drug": "PADCEV",
      "treatment": "Patients with muscle-invasive bladder cancer who a...",
      "pdufaDate": "2026-04-07",
      "approvalType": "NDA",
      "priority": "Standard",
      "status": "Pending",
      "description": "FDA decision on PADCEV plus KEYTRUDA for patients with muscle-invasive bladder cancer who are ineligible for cisplatin-containing chemotherapy"
    },
    {
      "id": "23",
      "company": "Merck & Co Inc.",
      "ticker": "MRK",
      "drug": "PADCEV",
      "treatment": "Patients with muscle-invasive bladder cancer who a...",
      "pdufaDate": "2026-04-07",
      "approvalType": "NDA",
      "priority": "Standard",
      "status": "Pending",
      "description": "FDA decision on PADCEV plus KEYTRUDA for patients with muscle-invasive bladder cancer who are ineligible for cisplatin-containing chemotherapy"
    },
    {
      "id": "24",
      "company": "AstraZeneca PLC",
      "ticker": "AZN",
      "drug": "PADCEV",
      "treatment": "Patients with muscle-invasive bladder cancer who a...",
      "pdufaDate": "2026-04-07",
      "approvalType": "NDA",
      "priority": "Standard",
      "status": "Pending",
      "description": "FDA decision on PADCEV plus KEYTRUDA for patients with muscle-invasive bladder cancer who are ineligible for cisplatin-containing chemotherapy"
    },
    {
      "id": "25",
      "company": "Merck & Co Inc.",
      "ticker": "MRK",
      "drug": "KEYTRUDA",
      "treatment": "Patients with muscle-invasive bladder cancer (mibc...",
      "pdufaDate": "2026-04-07",
      "approvalType": "NDA",
      "priority": "Standard",
      "status": "Pending",
      "description": "FDA decision on KEYTRUDA plus Padcev for the treatment of patients with muscle-invasive bladder cancer (MIBC) who are ineligible for cisplatin-based chemotherapy."
    },
    {
      "id": "26",
      "company": "Merck & Co Inc.",
      "ticker": "MRK",
      "drug": "KEYTRUDA QLEX",
      "treatment": "Patients with muscle-invasive bladder cancer (mibc...",
      "pdufaDate": "2026-04-07",
      "approvalType": "NDA",
      "priority": "Standard",
      "status": "Pending",
      "description": "FDA decision on KEYTRUDA QLEX plus Padcev for the treatment of patients with muscle-invasive bladder cancer (MIBC) who are ineligible for cisplatin-based chemotherapy."
    },
    {
      "id": "27",
      "company": "Bristol Myers Squibb Co.",
      "ticker": "BMY",
      "drug": "Opdivo",
      "treatment": "Previously untreated stage iii or iv classical hod...",
      "pdufaDate": "2026-04-08",
      "approvalType": "NDA",
      "priority": "Standard",
      "status": "Pending",
      "description": "FDA decision on Opdivo plus Chemotherapy combination for previously untreated Stage III or IV Classical Hodgkin Lymphoma"
    },
    {
      "id": "28",
      "company": "Replimune Group Inc.",
      "ticker": "REPL",
      "drug": "RP1",
      "treatment": "Advanced melanoma in patients who progress on an a...",
      "pdufaDate": "2026-04-10",
      "approvalType": "NDA",
      "priority": "Standard",
      "status": "Pending",
      "description": "FDA decision on RP1 in combination with Bristol Myers Squibb's Opdivo for the treatment of advanced melanoma in patients who progress on an anti-PD-1 containing regimen"
    },
    {
      "id": "10",
      "company": "Travere Therapeutics Inc",
      "ticker": "TVTX",
      "drug": "FILSPARI",
      "treatment": "Focal segmental glomerulosclerosis (fsgs)",
      "pdufaDate": "2026-04-13",
      "approvalType": "NDA",
      "priority": "Standard",
      "status": "Pending",
      "description": "FDA decision on FILSPARI (sparsentan) for the treatment of focal segmental glomerulosclerosis (FSGS)"
    },
    {
      "id": "29",
      "company": "Ligand Pharmaceuticals Inc",
      "ticker": "LGND",
      "drug": "FILSPARI",
      "treatment": "Focal segmental glomerulosclerosis (fsgs)",
      "pdufaDate": "2026-04-13",
      "approvalType": "NDA",
      "priority": "Standard",
      "status": "Pending",
      "description": "FDA decision on FILSPARI (sparsentan) for the treatment of focal segmental glomerulosclerosis (FSGS)"
    },
    {
      "id": "11",
      "company": "Sanofi SA",
      "ticker": "SNY",
      "drug": "Subcutaneous Sarclisa",
      "treatment": "Various conditions",
      "pdufaDate": "2026-04-23",
      "approvalType": "NDA",
      "priority": "Standard",
      "status": "Pending",
      "description": "FDA deciaion on subcutaneous Sarclisa in multiple myeloma"
    },
    {
      "id": "12",
      "company": "Grace Therapeutics, Inc.",
      "ticker": "GRCE",
      "drug": "GTx-104",
      "treatment": "Aneurysmal subarachnoid hemorrhage (asah)",
      "pdufaDate": "2026-04-23",
      "approvalType": "NDA",
      "priority": "Standard",
      "status": "Pending",
      "description": "FDA decision on GTx-104 for the treatment of aneurysmal Subarachnoid Hemorrhage (aSAH)"
    },
    {
      "id": "13",
      "company": "Sanofi SA",
      "ticker": "SNY",
      "drug": "Dupixent",
      "treatment": "Chronic spontaneous urticaria (csu) in children",
      "pdufaDate": "2026-04-27",
      "approvalType": "NDA",
      "priority": "Standard",
      "status": "Pending",
      "description": "FDA decision on Dupixent for the treatment of chronic spontaneous urticaria (CSU) in children"
    },
    {
      "id": "14",
      "company": "Merck & Co Inc.",
      "ticker": "MRK",
      "drug": "Doravirine/Islatravir",
      "treatment": "Adults with hiv-1 infection that is virologically ...",
      "pdufaDate": "2026-04-28",
      "approvalType": "NDA",
      "priority": "Standard",
      "status": "Pending",
      "description": "FDA decision on Doravirine/Islatravir, an oral, two-drug regimen for adults with HIV-1 infection that is virologically suppressed on antiretroviral therapy."
    },
    {
      "id": "15",
      "company": "Sanofi SA",
      "ticker": "SNY",
      "drug": "Tzield",
      "treatment": "Various conditions",
      "pdufaDate": "2026-04-29",
      "approvalType": "NDA",
      "priority": "Standard",
      "status": "Pending",
      "description": "FDA decision on Tzield to expand to as young as one year old and above to delay the onset of stage 3 type 1 diabetes in patients diagnosed with stage 2 T1D"
    },
    {
      "id": "16",
      "company": "Axsome Therapeutics, Inc.",
      "ticker": "AXSM",
      "drug": "AXS-05",
      "treatment": "Alzheimers disease agitation",
      "pdufaDate": "2026-04-30",
      "approvalType": "NDA",
      "priority": "Standard",
      "status": "Pending",
      "description": "FDA decision on AXS-05 for the treatment of Alzheimers disease agitation"
    },
    {
      "id": "17",
      "company": "argenx SE",
      "ticker": "ARGX",
      "drug": "VYVGART",
      "treatment": "Achr antibodies (seronegative)",
      "pdufaDate": "2026-05-10",
      "approvalType": "NDA",
      "priority": "Standard",
      "status": "Pending",
      "description": "FDA decision on VYVGART with generalized myasthenia gravis who test negative for AChR antibodies (seronegative)."
    },
    {
      "id": "18",
      "company": "Daiichi Sankyo Company Limited",
      "ticker": "DSKYF",
      "drug": "ENHERTU",
      "treatment": "The neoadjuvant treatment of adult patients with h...",
      "pdufaDate": "2026-05-18",
      "approvalType": "NDA",
      "priority": "Standard",
      "status": "Pending",
      "description": "FDA decision on ENHERTU followed by paclitaxel, trastuzumab and pertuzumab for the neoadjuvant treatment of adult patients with HER2 positive breast cancer"
    },
    {
      "id": "19",
      "company": "AstraZeneca PLC",
      "ticker": "AZN",
      "drug": "ENHERTU",
      "treatment": "The neoadjuvant treatment of adult patients with h...",
      "pdufaDate": "2026-05-18",
      "approvalType": "NDA",
      "priority": "Standard",
      "status": "Pending",
      "description": "FDA decision on ENHERTU followed by paclitaxel, trastuzumab and pertuzumab for the neoadjuvant treatment of adult patients with HER2 positive breast cancer"
    }
  ],
  "meta": {
    "source": "RTTNews",
    "sourceUrl": "https://www.rttnews.com/corpinfo/fdacalendar.aspx",
    "scrapedAt": "2026-02-11T02:59:57.744723",
    "itemCount": 37,
    "dateRange": {
      "earliest": "2026-02-20",
      "latest": "2026-05-18"
    }
  }
}